ABT reports Q2 non-GAAP EPS of $1.31, topping estimates by $0.03, and lifts full-year 2026 adjusted EPS guidance.
Abbott Laboratories posted Q2 non-GAAP earnings per share of $1.31, exceeding estimates by $0.03, as revenue rose 13% year-over-year to $12.59 billion, beating expectations by $70 million.
The company reaffirmed its 2026 comparable sales growth guidance of 6.5% to 7.5% but raised its full-year 2026 adjusted diluted EPS outlook, reflecting stronger-than-anticipated performance.
Shares showed limited immediate reaction in after-hours trading as investors digested the updated guidance and solid quarterly results.